You may not log in without verifying your email address.
Please check your email (including your spam email) for the Welcome message that was sent.
EX 527 is a potent and selective inhibitor of the SIRT1 class III histone deacetylase enzyme, thought to block the release of deacetylated peptide and O-acetyl-ADP-ribose from the enzyme following the deacetylation process. EX 527 has been used a powerful tool for studying the relationship between SIRT1 and cell regulation. The deacetylation of cortactin, a protein responsible for rearrangements of the actin cytoskeleton, is associated with cell motility and possibly tumorigenesis, and blocking of this deacetylation by EX 527 correlated to a decrease in cell motility. Blocking of SIRT1 by EX 527 also demonstrated that deacetylation of the important tumor suppressor protein p53 is mediated by SIRT1 as well. EX 527 inhibits other sirtuin family deacetylases only at much higher concentrations (IC50 = 19.6 and 48.7 μM for SIRT2 and SIRT3, respectively).
1. Napper, Andrew D., et al., 2005. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. Journal of medicinal chemistry. 48(25): 8045-54. PMID: 16335928
2. Solomon, Jonathan M., et al., 2006. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Molecular and cellular biology. 26(1): 28-38. PMID: 16354677
3. Milne, Jill C., et al., 2007. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 450(7170): 712-6. PMID: 18046409
4. Zhang, Y., et al., 2009. Deacetylation of cortactin by SIRT1 promotes cell migration. Oncogene. 28(3): 445-60. PMID: 18850005
See how others have used EX 527. Click on the entry to view the PubMed entry .
PMID: # 30917412 Igarashi, M.|Miura, M.|Williams, E.|Jaksch, F.|Kadowaki, T.|Yamauchi, T.|Guarente, L.| et al. 2019. Aging Cell. 18: e12935.
PMID: # 30213795 Funato, K.|Hayashi, T.|Echizen, K.|Negishi, L.|Shimizu, N.|Koyama-Nasu, R.|Nasu-Nishimura, Y.|Morishita, Y.|Tabar, V.|Todo, T.|Ino, Y.|Mukasa, A.|Saito, N.|Akiyama, T.| et al. 2018. EMBO Rep. 19:
PMID: # 28978059 Bhanot, H. et al. 2017. Oncotarget. 8: 67639-67650.
PMID: # 26891914 Graham, RM. et al. 2016. Experimental & molecular medicine. 48: e210.
PMID: # 26052531 Wielgosz, MM. et al. 2015. Molecular therapy. Methods & clinical development. 2: 14063.
PMID: # 25401748 Yang, Y. et al. 2015. Journal of pineal research. 58: 61-70.
PMID: # 25710021 He, W. et al. 2015. BioMed research international. 2015: 684242.
PMID: # 26307266 Guida, N. et al. 2015. Toxicology and applied pharmacology. 288: 387-98.
PMID: # 24982422 Rodriguez, M. et al. 2014. J Biol Chem. 289: 22942-22957.
PMID: # 24990896 Quadri, S. et al. 2014. American journal of physiology. Renal physiology. 307: F593-600.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.